A new mRNA-based cancer vaccine is showing early promise in targeting one of the most aggressive forms of cancer: pancreatic cancer.
"This represents a shift toward personalized oncology," said Dr. Hannah Collins. "We are training the immune system to recognize tumor-specific mutations."
The platform builds on the same technology used in COVID-19 vaccines but adapts it for individualized cancer treatment.
"The adaptability of mRNA platforms makes them one of the most powerful tools in modern medicine," added Dr. James Ortega.
Early clinical trials indicate improved immune responses and potential survival benefits.
Sources: New England Journal of Medicine; NIH Clinical Trials